Two hundred AI-designed drugs are now in human trials. Not one is approved.

Run time: 20:11

In today's episode:

1. Two hundred AI-discovered drugs in trials, zero approved
2. FDA clears Clarius bedside ejection-fraction AI
3. GE HealthCare auto-contouring tool cleared for radiation planning
4. Philips and WellSpan sign seven-year AI imaging alliance
5. Joint Commission launches first hospital AI certification
6. WHO weighs AI for health-policy decisions
7. Anthropic scales Mythos cyber program to fifteen countries
8. Perplexity lets its agent write its own search code
9. OpenAI says chat is dead, pivots to agents

TL;DR:

• The AI drug-discovery story matured into a counting problem: 200-plus candidates in clinical trials, roughly 56 in Phase 2 and 15 in Phase 3, and still zero FDA approvals. The 2026 Phase 3 readouts (zasocitinib, more rentosertib data) are the real test.
• Two more FDA clearances landed this week — Clarius for bedside ejection fraction, GE HealthCare for radiation-oncology auto-contouring — both narrow, both incremental, both shipping into existing workflows rather than replacing anyone.
• Governance caught up to deployment: the Joint Commission's Responsible Use of AI certification went live June 1, the first accreditation-grade AI program built specifically for health systems.

Sources cited:

• BioMed Nexus
• DAIC
• ITN
• Philips
• Joint Commission
• WHO
• TechCrunch
• The Decoder
• the AAPM TG-275/TG-132 segmentation guidance and reviews on auto-segmentation QA

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.